Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational ProgressBusiness Wire • 11/04/21
Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021Business Wire • 10/28/21
Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021Business Wire • 10/13/21
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)Business Wire • 10/04/21
Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021Business Wire • 09/29/21
European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)Business Wire • 09/27/21
Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual ConferenceBusiness Wire • 09/02/21
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/09/21
Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational ProgressBusiness Wire • 08/09/21
Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of DirectorsBusiness Wire • 08/09/21
Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021Business Wire • 08/02/21
Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry GamechangersBusiness Wire • 07/01/21
Atara Biotherapeutics Reveals Long-Term Overall Survival Data in Solid Organ-Transplant PatientsBenzinga • 06/07/21
Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual ConnectBusiness Wire • 06/07/21
Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation SummitBusiness Wire • 05/13/21
Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific OfficerBusiness Wire • 05/10/21
Atara Biotherapeutics' (ATRA) CEO Pascal Touchon on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/05/21
Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational ProgressBusiness Wire • 05/04/21
Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021Business Wire • 04/27/21
Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual MeetingBusiness Wire • 03/14/21
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/02/21